Evidence map›Paper›PMID 37515105›Full record

ArticleViruses2023

COVID-19: S-Peptide RBD

Michela Murdocca, Gennaro Citro, Eleonora Centanini, Rosalinda Giannini, Andrea Latini, Federica Centofanti, Eva Piano Mortari, Dario Cocciadiferro, Antonio Novelli, Sergio Bernardini and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Michela MurdoccaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Gennaro CitroDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Eleonora CentaniniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Rosalinda GianniniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Andrea LatiniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Federica CentofantiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Eva Piano MortariB Cell Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Dario CocciadiferroMedical Genetics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Antonio NovelliMedical Genetics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.ORCID 0000-0002-9037-4297
Sergio BernardiniDepartment of Experimental Medicine, University of Tor Vergata, 00133 Rome, Italy.
Giuseppe NovelliDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-7781-602X
Federica SangiuoloDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6227-4248
University of Rome Tor Vergata · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the availability on the market of different anti-SARS-CoV-2 vaccines, there are still unanswered questions on whether they can stimulate long-lasting protection. A deep understanding of adaptive immune response to SARS-CoV-2 is important for optimizing both vaccine development and pandemic control measures. Among cytokines secreted by lymphocytes in response to viral infection, IFN-γ plays a pivotal role both in innate and adaptive immunity. In this study, we report on 28 naïve-to-SARS-Cov-2-infection and unvaccinated subjects, having reported a close and prolonged contact with COVID-19-positive patients. Samples were tested for defective genetic variants in interferon pathway genes by whole exome sequencing and anti-IFN autoantibodies production was investigated. Subject T-cells were cultured and infected with pseudotype particles bearing the S proteins and in parallel stimulated with two S-peptides designed on the RBD region of the spike protein. Our results showed that one of these peptides, RBD 484-508, induces a significant increase in IFN-γ gene expression and protein production in T-cells, comparable to those obtained in cells infected by SARS-CoV-2 pseudovirus. This work deepens our understanding of immune response and highlights the selected peptide as a reasonable approach to induce broad, potent, and variant concern-independent T-cell responses.

Indexed as

COVID-19Antibodies, ViralHumansInterferon-gammaPeptidesSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesAntibodies, ViralInterferon-gammaPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2IFN-γpeptidepseudovirusSARS-CoV-2

Identifiers

PMID37515105
PMCPMC10386297
OpenAlexW4381803692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.